IGC Pharma Secures Two Awards in NIH's AI PREPARE Challenge

IGC Pharma, Inc., a biotechnology firm, has achieved notable success by winning two prizes in the Phase 1 of the PREPARE Challenge organized by the National Institute on Aging. The challenge aims to enhance tools for early prediction of Alzheimer's and related dementias. IGC's Mexican Health and Aging Study database earned the Disproportionate Impact prize, recognizing its potential to aid algorithms targeting disproportionately affected populations, and secured third place overall.

Currently, there are around 400 million people in the early stages of Alzheimer's, showing signs like plaque buildup that could lead to cognitive decline over two decades. IGC is leveraging deep learning models to develop accessible diagnostic tools that predict such declines while avoiding costly imaging techniques.

CEO Ram Mukunda expressed the company's commitment to improving outcomes for patients and reducing healthcare costs through early prediction. This aligns with IGC's broader strategy of pursuing AI-driven innovations in Alzheimer's care and mitigating the condition's projected economic impact.